Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy
– Company has raised $50 million since its inception – – Funds will advance RespiRx™ Nicotine Inhaler to Marketing Authorization Application (MAA) submission and accelerate the path to commercialization in the UK – RICHMOND, Va., Dec. 10, 2024 /PRNewswire/ — Qnovia,…